Trial Profile
A Multicenter, Prospective Cohort Study to Provide Real-world Evidence on the Effect of Nab-paclitaxel (ABRAXANE) Treatment on the Clinical Outcomes and Health-related Quality of Life in Patients With Metastatic Breast Cancer in Greece. The 'ABReast' Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms ABReast
- Sponsors Genesis Pharma
- 14 Dec 2019 Results (N=150), evaluating efficacy and safety of nab-paclitaxel through real world evidence, presented at the 42nd Annual San Antonio Breast Cancer Symposium
- 19 May 2019 Status changed from active, no longer recruiting to completed.
- 25 Oct 2017 Status changed from recruiting to active, no longer recruiting.